ストックスクリーナーアプリを入手
10.42
3.07%
0.31
プレマーケット:
10.46
0.04
+0.38%
Vir Biotechnology Inc (VIR) 最新ニュース
Vir Biotechnology Phase 1 Data on Dual-Masked T-Cell Engagers (TCEs) – Market - HPBL
Vir Biotechnology Inc. (VIR) Stock Overview and Recent Developments – Market - HPBL
Vir Biotechnology Shares Surge After Opening Higher: A Market Overview – Market - HPBL
What is Leerink Partnrs’ Forecast for VIR Q1 Earnings? - Defense World
Analysts Set Vir Biotechnology, Inc. (NASDAQ:VIR) PT at $34.83 - Defense World
Vir Biotechnology (NASDAQ:VIR) Shares Down 10.4%Here's What Happened - MarketBeat
Q1 Earnings Estimate for VIR Issued By Leerink Partnrs - MarketBeat
JPMorgan Chase & Co. Has $8.14 Million Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
Q2 Earnings Estimate for VIR Issued By Leerink Partnrs - MarketBeat
Analysts Set Vir Biotechnology, Inc. (NASDAQ:VIR) Price Target at $34.83 - MarketBeat
Leerink Partners Boosts Vir Biotechnology (NASDAQ:VIR) Price Target to $20.00 - MarketBeat
Nordea Investment Management AB Sells 286,600 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20 - MSN
Vir Biotechnology Catapults 58% On Promising Results In Cancer Treatment - MSN
Morgan Stanley Doubles Vir Biotechnology Price ForecastHere's Why - AOL
Vir Biotechnology (NASDAQ:VIR) Earns "Buy" Rating from HC Wainwright - MarketBeat
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates - MSN
Morgan Stanley Upgrades Vir Biotechnology (VIR) - MSN
Vir Biotech upgraded at Morgan Stanley on cancer drug data - MSN
Vir Biotechnology Reports Positive Phase 2 Results, Shares Surge by 58% - GuruFocus.com
Insider Sell: Vicki Sato Sells Shares of Vir Biotechnology Inc (VIR) - GuruFocus.com
Vir Biotechnology: A Rocket Off Phase 1 Data... What Could Go Wrong? (NASDAQ:VIR) - Seeking Alpha
Vir Biotechnology (NASDAQ:VIR) Upgraded by Morgan Stanley to "Overweight" Rating - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Given New $14.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20 By Investing.com - Investing.com Canada
Vir Biotechnology Reports Promising Trial Results for Cancer Therapies - Yahoo Finance
Morgan Stanley Sees 67% Upside Potential for Vir Biotechnology S - GuruFocus.com
Morgan Stanley Sees 67% Upside Potential for Vir Biotechnology Stock - Yahoo Finance
Vir Biotechnology stock soars 58%: Is it still a buy? - Dataconomy
Vir Biotechnology (NASDAQ:VIR) Sets New 52-Week HighHere's Why - MarketBeat
Vir Biotechnology director Vicki L. Sato sells $137,219 in stock By Investing.com - Investing.com Australia
Vir Biotechnology Catapults 62% On Promising Results In Cancer Treatment - MSN
Vir Biotechnology director Vicki L. Sato sells $137,219 in stock - Investing.com India
JPMorgan raises Vir Biotechnology stock target to $14 By Investing.com - Investing.com Canada
Vir Biotechnology price target raised to $14 from $10 at JPMorgan - MSN
Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells 10,960 Shares of Stock - MarketBeat
Vir Scores In Oncology Pivot With Strong Early T-Cell Engager Results - Citeline News & Insights
Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer - MSN
Top Midday Gainers - Marketscreener.com
Vir Biotechnology stock hits 52-week high of $13.18 By Investing.com - Investing.com Canada
Vir Biotechnology, Inc. (NASDAQ: VIR) Stock Surges 29% on Promising Cancer Treatment Data - HPBL
Vir Biotechnology Stock Soars On Prostate Cancer Trial DataHere's Why - Benzinga
Vir Biotechnology (NASDAQ:VIR) Shares Gap UpHere's Why - MarketBeat
Investors Purchase High Volume of Call Options on Vir Biotechnology (NASDAQ:VIR) - MarketBeat
4.81%
大文字化:
|
ボリューム (24 時間):